Saturday 17 October 2026
Export BCTX’s income statement to Excel — free account
BRIACELL THERAP
BCTX Healthcare Biotechnology
In the quarter to April 2026, EPS grew 94.0% and free cash flow was flat, each against the same quarter a year earlier.
3.42
0.35
−9.28%
Follow BCTX
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 270.00 | 270.00 | 150.00 | 60.00 | 32.50 | 28.10 | 40.60 | 36.70 | 4.60 | 3.50 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | 930.00 | 540.00 | 420.00 | 390.00 | 203.60 | 124.70 | 120.90 | 81.00 | 59.70 | 98.20 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | 5 | 12 | 12 | 18 | 22 | ||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | |||||
| EBT | (2) | (2) | (4) | (4) | (4) | (14) | (27) | (20) | (5) | (27) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | (2) | (2) | (4) | (4) | (4) | (14) | (27) | (20) | (5) | (27) | |||||
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (908.64) | (908.64) | (1,362.95) | (908.55) | (779.61) | (458.27) | (259.37) | (194.90) | (43.48) | (62.19) | |||||
| Cash flow | (622.95) | (655.68) | (1,390.89) | (1,012.82) | (263.73) | (257.48) | (120.86) | (227.88) | (219.93) | (66.58) | |||||
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (4.16) | 0.00 | |||||
| Free cash flow | (622.95) | (655.68) | (1,390.89) | (1,012.82) | (263.73) | (257.48) | (120.86) | (227.88) | (224.09) | (66.58) | |||||
| Book value | 408.89 | 320.41 | 345.39 | (168.21) | (749.46) | 919.33 | 99.99 | (36.25) | (24.47) | 40.97 | |||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (1) | (1) | (4) | (4) | (1) | (8) | (12) | (24) | (24) | (28) | ||||
| Capex | 0 | 0 | — | — | — | — | — | — | 0 | — | |||||
| Free cash flow | (1) | (1) | (4) | (4) | (1) | (8) | (12) | (24) | (25) | (28) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 1 | 1 | 1 | (1) | (4) | 57 | 41 | 25 | (4) | 16 | ||||
| Total debt | — | — | 1 | 0 | 0 | — | — | — | — | — | |||||
| Net debt | (1) | (2) | (1) | 0 | 0 | (57) | (41) | (21) | (1) | (18) | |||||
| Shareholders’ equity | 1 | 1 | 1 | (1) | (4) | 28 | 10 | (4) | (3) | 17 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (151.89) | (205.57) | (219.39) | (317.98) | (860.95) | (47.18) | (53.35) | (58.22) | (29.01) | (191.21) | ||||
| ROIC | 0.00 | 0.00 | (754.89) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | (164.96) | (327.70) | (508.50) | (2,667.58) | 189.99 | (114.78) | (141.26) | (619.76) | 148.30 | (359.23) | |||||
Negative figures in brackets.
Fundamentals updated 2 Oct 2026
Charts ten years each
BRIACELL THERAP vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CRVO CervoMed Inc. | $34.0M | — (loss-making) | — (loss-making) | −99.60% (below 0%: shrinking) | n/m | −6.20% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| IRLA Quince Therapeutics, Inc. | $33.8M | — (loss-making) | — | — | n/m | −63.65% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ALGS Aligos Therapeutics, Inc. | $33.7M | — (loss-making) | — (loss-making) | +2,778.55% (above 0%: growing) | n/m | −59.81% (below 0%: shrinking) | 100.00% | (6.80%) | Compare |
| ATNM Actinium Pharmaceuticals, Inc. | $33.3M | 3.1× | — (loss-making) | +77,677.78% (above 0%: growing) | n/m | −4.91% (below 0%: shrinking) | 100.00% | 78.76% | Compare |
| BCTX BRIACELL THERAP | $32.8M | 1.5× | — | — | n/m | +0.21% (above 0%: growing) | 0.00% | 0.00% | |
| GNTA Genenta Science S.p.A. Unsponsored ADR | $32.3M | — | — | — | — | +35.94% (above 0%: growing) | 0.00% | — | Compare |
| MGX Metagenomi Therapeutics, Inc. | $31.9M | — (loss-making) | — (loss-making) | −103.02% (below 0%: shrinking) | n/m | +7.98% (above 0%: growing) | 100.00% | 11,195.72% | Compare |
| GRDX GridAI Technologies Corp. | $31.8M | — (loss-making) | — | — | n/m | −2,640.98% (below 0%: shrinking) | (42.49%) | (15,258.21%) | Compare |
| NXTC NextCure, Inc. | $31.5M | — (loss-making) | — (loss-making) | +1,549.08% (above 0%: growing) | n/m | +57.23% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $32.8M | — | — | +1,549.08% | — | −5.55% | 50.00% | 0.00% |
BRIACELL THERAP (BCTX) key facts
- BRIACELL THERAP (BCTX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, BCTX traded at $3.42, a market capitalization of $32.8 million.
- Return on equity was −359.2% and debt-to-equity 0.00.